Current Path : /storage/v11800/abaniliving-com/public_html/wp-content/plugins/wpforms-lite/assets/css/builder/

Linux v11800 5.3.0-1023-aws #25~18.04.1-Ubuntu SMP Fri Jun 5 15:19:18 UTC 2020 aarch64

Upload File :
Current File : /storage/v11800/abaniliving-com/public_html/wp-content/plugins/wpforms-lite/assets/css/builder/builder-overlay.css
#wpforms-builder-overlay {
  background: radial-gradient(50% 50% at 50% 50%, #f8f8f8 37.5%, #e8e8e8 100%);
  cursor: default;
  height: 100%;
  min-width: 0;
  overflow: hidden;
  position: fixed;
  z-index: 100;
  top: 0;
  right: 0;
  bottom: 0;
  left: 0;
  transition-property: opacity;
  transition-duration: 0.5s;
  transition-timing-function: ease-out;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

#wpforms-builder-overlay.fade-out {
  opacity: 0;
}

.wpforms-builder-overlay-content {
  text-align: center;
  position: relative;
  height: 100px;
  width: 100px;
}

.wpforms-builder-overlay-content i {
  display: block;
  position: absolute;
  left: 0;
  top: 0;
}

.wpforms-builder-overlay-content i.spinner {
  background-image: url("../../images/builder/loading-spinner.svg");
  border-radius: 50%;
  height: 100px;
  width: 100px;
  -webkit-animation: wpforms-spinner-rotation 0.8s linear infinite;
  -moz-animation: wpforms-spinner-rotation 0.8s linear infinite;
  -ms-animation: wpforms-spinner-rotation 0.8s linear infinite;
  -o-animation: wpforms-spinner-rotation 0.8s linear infinite;
  animation: wpforms-spinner-rotation 0.8s linear infinite;
}

.wpforms-builder-overlay-content i.avatar {
  background-color: #ffffff;
  background-image: url("../../images/builder/loading-avatar.svg");
  border-radius: 50%;
  box-shadow: 0 2px 5px rgba(0, 0, 0, 0.15);
  height: 80px;
  margin: 10px;
  width: 80px;
}

@keyframes wpforms-spinner-rotation {
  from {
    transform: rotate(0deg);
  }
  to {
    transform: rotate(360deg);
  }
}

/*# sourceMappingURL=data:application/json;charset=utf8;base64,{"version":3,"file":"assets/css/builder/builder-overlay.css","sources":["assets/scss/builder/builder-overlay.scss","assets/scss/builder/partials/_common.scss","assets/scss/builder/partials/_colors.scss","assets/scss/builder/partials/_variables.scss","assets/scss/builder/partials/_mixins.scss","assets/scss/builder/partials/_mixins-buttons.scss","assets/scss/builder/partials/_overlay.scss"],"sourcesContent":["// Form Builder styles.\n//\n// Overlay (main spinner) styles.\n//\n// @since 1.6.8\n\n@import 'partials/common';\n\n@import 'partials/overlay';\n","// Form Builder styles.\n//\n// Common styles.\n//\n// @since 1.6.8\n\n@import 'colors';\n@import 'variables';\n@import 'mixins';\n@import 'mixins-buttons';\n","// Form Builder styles.\n//\n// Colors.\n//\n// @since 1.6.8\n\n// Colors by name:\n$color_white:                          #ffffff;\n$color_black:                          #2d2d2d;\n\n$color_dark_red:                       #b32d2e;\n$color_red:                            #d63638;\n$color_bright_red:                     #ee5c5c;\n$color_lightest_red:                   #fcf0f1;\n\n$color_dark_green:                     #008a20;\n$color_green:                          #00a32a;\n$color_lightest_green:                 #edfaef;\n$color_darker_blue:                    #005387;\n$color_dark_blue:                      #215d8f;\n$color_blue:                           #036aab;\n$color_bright_blue:                    #0399ed;\n$color_bright_blue_alt:                #4285f4;\n$color_brighter_blue:                  #00c6bf;\n$color_light_blue:                     #79c2f4;\n$color_lighter_blue:                   #cce0ed;\n$color_lightest_blue:                  #f1f6fa;\n\n$color_dark_orange:                    #cd6622;\n$color_orange:                         #e27730;\n$color_light_orange:                   #f48120;\n\n$color_dark_yellow:                    #ffaa00;\n$color_yellow:                         #ffb900;\n$color_lightest_yellow:                #fcf9e8;\n\n$color_darker_grey:                    #626262;\n$color_dark_grey:                      #666666;\n$color_bright_grey:                    #aaaaaa;\n$color_bright_grey_alt:                #b6b6b6;\n$color_brighter_grey:                  #cccccc;\n$color_brighter_grey_alt:              #d6d6d6;\n$color_brightest_grey:                 #e8e8e8;\n$color_light_grey:                     #f1f1f1;\n$color_lighter_grey:                   #f6f6f6;\n$color_lightest_grey:                  #f8f8f8;\n\n// Colors by usage:\n$color_black_background:               #2d2d2d;\n$color_black_background_hover:         #444444;\n$color_dark_grey_background:           #6d6d6d;\n$color_grey_background:                #eeeeee;\n$color_grey_background_hover:          #d7d7d7;\n$color_light_background:               #f8f8f8;\n$color_light_background_hover:         #eeeeee;\n$color_light_background_notice:        #f0f0f0;\n\n$color_divider:                        #dddddd;\n$color_border:                         #cccccc;\n$color_border_hover:                   #999999;\n$color_hint:                           #bbbbbb;\n$color_primary_text:                   #444444;\n$color_secondary_text:                 #777777;\n$color_light_text:                     #86919e;\n$color_lighter_text:                   #999999;\n\n$color_fields_tabs:                    #e0e8f0;\n$color_fields_divider:                 #ced7e0;\n$color_fields_background:              #ebf3fc;\n$color_fields_background_hover:        #e0e8f0;\n$color_fields_border:                  #b0b6bd;\n$color_fields_hint:                    #b0b6bd;\n$color_fields_secondary_text:          #86919e;\n$color_preview_button_background:      #999999;\n\n$color_close:                          #bbbbbb;\n$color_close_hover:                    #777777;\n\n$color_button_icon_light_grey:         #a6a6a6;\n$color_button_icon_grey:               #999999;\n\n// Semitransparent colors:\n$color_white_trans_35:                 rgba( 255, 255, 255, .35 );\n$color_white_trans_65:                 rgba( 255, 255, 255, .65 );\n$color_white_trans_60:                 rgba( 255, 255, 255, .6 );\n$color_white_trans_50:                 rgba( 255, 255, 255, .5 );\n$color_black_trans_35:                 rgba( 0, 0, 0, .35 );\n$color_black_trans_15:                 rgba( 0, 0, 0, .15 );\n\n$color_scrollbar:                      rgba( 0, 0, 0, 0 );\n$color_scrollbar_hover:                rgba( 0, 0, 0, .5 );\n\n$color_box_shadow:                     rgba( 0, 0, 0, .1 );\n\n// We need this var since $blue used in `_choices.scss`,\n// which is used in the `admin.scss` as well.\n$blue: $color_blue;\n","// Form Builder styles.\n//\n// Variables.\n//\n// @since 1.6.8\n\n// Font sizes.\n$font_size_2xs:      11px;\n$font_size_xs:       12px;\n$font_size_ss:       13px;\n$font_size_s:        14px;\n$font_size_m:        16px;\n$font_size_l:        18px;\n$font_size_ll:       20px;\n$font_size_xl:       24px;\n$font_size_xxl:      28px;\n\n// Font family.\n$font_general:        -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, Oxygen-Sans, Ubuntu, Cantarell, \"Helvetica Neue\", sans-serif;\n$font_mono:           monospace;\n$font_fa:             FontAwesome;\n\n// Spacing.\n$spacing_xs:          5px;\n$spacing_ss:          8px;\n$spacing_s:           10px;\n$spacing_ms:          15px;\n$spacing_m:           20px;\n$spacing_ml:          25px;\n$spacing_l:           30px;\n$spacing_ll:          35px;\n$spacing_xl:          40px;\n$spacing_xll:         45px;\n$spacing_xxl:         50px;\n\n// Border radius.\n$border_radius_xs:    3px;\n$border_radius_s:     4px;\n$border_radius_m:     6px;\n\n// Border.\n$border_std:          1px solid $color_border;\n\n// Transitions.\n$transition_slowest:  .50s;\n$transition_slower:   .40s;\n$transition_slow:     .25s;\n$transition_normal:   .15s;\n$transition_fast:     .05s;\n\n// Dimensions.\n$toolbar_height:      76px;\n$panels_toggle_width: 95px;\n$sidebar_width:       400px;\n$option_toggle_width: 13px;\n\n// Field preview size.\n$field_size_small:    25%;\n$field_size_medium:   60%;\n$field_size_large:    100%;\n\n$field_min_width:     250px;\n\n// Choices icons path.\n$choices-button-icon-path: '../../images';\n","// Form Builder styles.\n//\n// Mixins.\n//\n// @since 1.6.8\n\n// Animation.\n//\n// @since 1.6.8\n//\n// @param $keyframes Animation keyframes name.\n//\n@mixin animation( $keyframes ) {\n\n\t-webkit-animation: $keyframes;\n\t-moz-animation: $keyframes;\n\t-ms-animation: $keyframes;\n\t-o-animation: $keyframes;\n\tanimation: $keyframes;\n}\n\n// Scrollbar.\n//\n// @since 1.6.8\n//\n// @param $width            Scrollbar width.\n// @param $track_background Track background.\n// @param $thumb_background Thumb background.\n//\n@mixin scrollbar( $width, $track_background, $thumb_background, $margin: 5px ) {\n\n\t// Webkit browsers.\n\t&::-webkit-scrollbar {\n\t\tbackground: $track_background;\n\t\twidth: #{ $width + $margin * 2 };\n\t\theight: #{ $width + $margin * 2 };\n\t}\n\n\t&::-webkit-scrollbar-track {\n\t\tbackground: $track_background;\n\t}\n\n\t&::-webkit-scrollbar-thumb {\n\t\tbox-shadow: inset 0 0 $width $width $thumb_background;\n\t\tbackground: transparent;\n\t\tborder-radius: #{ ( $width + $margin * 2 ) };\n\t\tborder: solid ( $margin - 1px ) transparent;\n\t}\n\n\t&::-webkit-resizer,\n\t&::-webkit-scrollbar-button,\n\t&::-webkit-scrollbar-corner {\n\t\tdisplay: none;\n\t}\n\n\t// For Firefox only.\n\t@-moz-document url-prefix() {\n\t\tscrollbar-color: $thumb_background $track_background;\n\t\tscrollbar-gutter: initial !important;\n\n\t\t@if $width <= 8px {\n\t\t\tscrollbar-width: thin;\n\t\t}\n\t}\n}\n\n// Transition.\n//\n// @since 1.6.8\n//\n// @param $elements Elements.\n// @param $duration Duration.\n// @param $easy     Duration.\n//\n@mixin transition( $elements, $duration, $easy ) {\n\n\ttransition-property: #{$elements};\n\ttransition-duration: #{$duration};\n\ttransition-timing-function: #{$easy};\n}\n\n// Focus visible.\n//\n// @since 1.6.8\n//\n@mixin focus_visible() {\n\n\toutline-offset: 0;\n\toutline: 1px dotted $color_black_trans_35;\n}\n\n// Font smoothing.\n//\n// @since 1.6.8\n//\n@mixin font_smoothing() {\n\n\t-webkit-font-smoothing: antialiased;\n\t-moz-osx-font-smoothing: grayscale;\n}\n\n// Inset absolute and fixed positioned element.\n//\n// @since 1.6.8\n//\n@mixin inset_0() {\n\n\ttop: 0;\n\tright: 0;\n\tbottom: 0;\n\tleft: 0;\n}\n\n// Centering on both axes.\n//\n// @since 1.6.8\n//\n@mixin flex_center_both_axes() {\n\n\tdisplay: flex;\n\tflex-direction: column;\n\tjustify-content: center;\n\talign-items: center;\n}\n\n// Reset appearance.\n//\n// @since 1.6.8\n//\n@mixin reset_appearance() {\n\n\tappearance: none;\n\t-webkit-appearance: none;\n}\n\n// Unflippable ChoicesJS\n//\n// @since 1.7.9\n//\n@mixin choicesjs_unflippable() {\n\n\ttop: 100%;\n\tbottom: auto;\n\tmargin-top: -1px;\n\tmargin-bottom: 0;\n}\n\n// Loading spinner\n//\n// @since 1.8.8\n//\n@mixin loading_spinner( $spinner-directory: '../images' ) {\n\n\t.wpforms-loading-spinner {\n\t\tbackground-image: url( \"#{ $spinner-directory }/spinner.svg\" );\n\t\tbackground-repeat: no-repeat;\n\t\tbackground-size: 15px 15px;\n\t\tbackground-position: center;\n\t\tdisplay: block;\n\t\theight: 15px;\n\t\tmargin: 0 $spacing_s 0 0;\n\t\tvertical-align: -2px;\n\t\twidth: 15px;\n\n\t\t@include animation( wpforms-spinner-rotation .8s linear infinite );\n\n\t\t&.wpforms-loading-white {\n\t\t\tbackground-image: url( \"#{ $spinner-directory }/spinner-white.svg\" );\n\t\t}\n\n\t\t&.wpforms-loading-blue {\n\t\t\tbackground-image: url( \"#{ $spinner-directory }/spinner-blue.svg\" );\n\t\t\tbackground-size: 14px 15px;\n\t\t}\n\n\t\t&.wpforms-loading-md {\n\t\t\tbackground-size: 24px 24px;\n\t\t\theight: 24px;\n\t\t\twidth: 24px;\n\t\t}\n\n\t\t&.wpforms-loading-inline {\n\t\t\tdisplay: inline-block;\n\t\t\tmargin: auto;\n\t\t}\n\t}\n\n\t@keyframes wpforms-spinner-rotation {\n\t\tfrom {\n\t\t\ttransform: rotate( 0deg );\n\t\t}\n\t\tto {\n\t\t\ttransform: rotate( 360deg );\n\t\t}\n\t}\n}\n","// Form Builder styles.\n//\n// Buttons mixins.\n//\n// @since 1.6.8\n\n// WPForms Button.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn() {\n\n\tborder-width: 1px;\n\tborder-style: solid;\n\tborder-radius: $border_radius_s;\n\tcursor: pointer;\n\tdisplay: inline-block;\n\tmargin: 0;\n\ttext-decoration: none;\n\ttext-align: center;\n\tvertical-align: middle;\n\twhite-space: nowrap;\n\tbox-shadow: none;\n\n\t@include transition( all, $transition_fast, ease-in );\n}\n\n// WPForms Button Small.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_sm() {\n\n\tfont-size: $font_size_s;\n\tfont-weight: 500;\n\tpadding: 0 $spacing_s;\n\theight: 32px;\n\tline-height: 30px;\n}\n\n// WPForms Button Medium.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_md() {\n\n\tfont-size: $font_size_s;\n\tfont-weight: 600;\n\tline-height: $font_size_s + 3;\n\tpadding: $spacing_s $spacing_ms;\n}\n\n// WPForms Button Large.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_lg() {\n\n\tfont-size: $font_size_m;\n\tfont-weight: 600;\n\tpadding: 16px 28px;\n}\n\n// WPForms Button Blue.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_blue() {\n\n\tbackground-color: $color_blue;\n\tborder-color: $color_blue;\n\tcolor: $color_white;\n\n\t&:hover {\n\t\tbackground-color: $color_dark_blue;\n\t\tborder-color: $color_dark_blue;\n\t\tcolor: $color_white;\n\t}\n}\n\n// WPForms Button Orange.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_orange() {\n\n\tbackground-color: $color_orange;\n\tborder-color: $color_orange;\n\tcolor: $color_white;\n\n\t&:hover {\n\t\tbackground-color: $color_dark_orange;\n\t\tborder-color: $color_dark_orange;\n\t\tcolor: $color_white;\n\t}\n}\n\n// WPForms Button Grey.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_grey() {\n\n\tbackground-color: $color_grey_background;\n\tborder-color: $color_border;\n\tcolor: $color_secondary_text;\n\n\t&:hover {\n\t\tbackground-color: $color_grey_background_hover;\n\t\tborder-color: $color_border;\n\t\tcolor: $color_primary_text;\n\t}\n}\n\n// WPForms Button Light Grey.\n//\n// @since 1.6.8\n//\n@mixin wpforms_btn_light_grey() {\n\n\tbackground-color: $color_light_background;\n\tborder-color: $color_border;\n\tcolor: $color_secondary_text;\n\n\t&:hover {\n\t\tbackground-color: $color_light_background_hover;\n\t\tborder-color: $color_border;\n\t\tcolor: $color_primary_text;\n\t}\n}\n","// Form Builder styles.\n//\n// Overlay.\n//\n// @since 1.6.8\n\n#wpforms-builder-overlay {\n\tbackground: radial-gradient( 50% 50% at 50% 50%, $color_lightest_grey 37.5%, $color_brightest_grey 100% );\n\tcursor: default;\n\theight: 100%;\n\tmin-width: 0;\n\toverflow: hidden;\n\tposition: fixed;\n\tz-index: 100; // Inside (related to) the main builder container #wpforms-builder.\n\n\t@include inset_0();\n\t@include transition( opacity, $transition_slowest, ease-out );\n\t@include flex_center_both_axes();\n\n\t&.fade-out {\n\t\topacity: 0;\n\t}\n}\n\n.wpforms-builder-overlay-content {\n\ttext-align: center;\n\tposition: relative;\n\theight: 100px;\n\twidth: 100px;\n\n\ti {\n\t\tdisplay: block;\n\t\tposition: absolute;\n\t\tleft: 0;\n\t\ttop: 0;\n\n\t\t&.spinner {\n\t\t\tbackground-image: url( \"../../images/builder/loading-spinner.svg\" );\n\t\t\tborder-radius: 50%;\n\t\t\theight: 100px;\n\t\t\twidth: 100px;\n\t\t\t@include animation( wpforms-spinner-rotation .8s linear infinite );\n\t\t}\n\n\t\t&.avatar {\n\t\t\tbackground-color: $color_white;\n\t\t\tbackground-image: url( \"../../images/builder/loading-avatar.svg\" );\n\t\t\tborder-radius: 50%;\n\t\t\tbox-shadow: 0 2px 5px rgba( 0, 0, 0, .15 );\n\t\t\theight: 80px;\n\t\t\tmargin: $spacing_s;\n\t\t\twidth: 80px;\n\t\t}\n\t}\n}\n\n@keyframes wpforms-spinner-rotation {\n\tfrom {\n\t\ttransform: rotate( 0deg );\n\t}\n\tto {\n\t\ttransform: rotate( 360deg );\n\t}\n}\n"],"names":[],"mappings":"AMMA,AAAA,wBAAwB,CAAC;EACxB,UAAU,EAAE,gEAA6F;EACzG,MAAM,EAAE,OAAO;EACf,MAAM,EAAE,IAAI;EACZ,SAAS,EAAE,CAAC;EACZ,QAAQ,EAAE,MAAM;EAChB,QAAQ,EAAE,KAAK;EACf,OAAO,EAAE,GAAG;EF8FZ,GAAG,EAAE,CAAC;EACN,KAAK,EAAE,CAAC;EACR,MAAM,EAAE,CAAC;EACT,IAAI,EAAE,CAAC;EAlCP,mBAAmB,EAAC,OAAC;EACrB,mBAAmB,EAAC,IAAC;EACrB,0BAA0B,EAAC,QAAC;EAyC5B,OAAO,EAAE,IAAI;EACb,cAAc,EAAE,MAAM;EACtB,eAAe,EAAE,MAAM;EACvB,WAAW,EAAE,MAAM;CEpGnB;;AAhBD,AAaC,wBAbuB,AAatB,SAAS,CAAC;EACV,OAAO,EAAE,CAAC;CACV;;AAGF,AAAA,gCAAgC,CAAC;EAChC,UAAU,EAAE,MAAM;EAClB,QAAQ,EAAE,QAAQ;EAClB,MAAM,EAAE,KAAK;EACb,KAAK,EAAE,KAAK;CA0BZ;;AA9BD,AAMC,gCAN+B,CAM/B,CAAC,CAAC;EACD,OAAO,EAAE,KAAK;EACd,QAAQ,EAAE,QAAQ;EAClB,IAAI,EAAE,CAAC;EACP,GAAG,EAAE,CAAC;CAmBN;;AA7BF,AAYE,gCAZ8B,CAM/B,CAAC,AAMC,QAAQ,CAAC;EACT,gBAAgB,EAAE,+CAAiD;EACnE,aAAa,EAAE,GAAG;EAClB,MAAM,EAAE,KAAK;EACb,KAAK,EAAE,KAAK;EF1Bd,iBAAiB,EE2BK,wBAAwB,CAAC,IAAG,CAAC,MAAM,CAAC,QAAQ;EF1BlE,cAAc,EE0BQ,wBAAwB,CAAC,IAAG,CAAC,MAAM,CAAC,QAAQ;EFzBlE,aAAa,EEyBS,wBAAwB,CAAC,IAAG,CAAC,MAAM,CAAC,QAAQ;EFxBlE,YAAY,EEwBU,wBAAwB,CAAC,IAAG,CAAC,MAAM,CAAC,QAAQ;EFvBlE,SAAS,EEuBa,wBAAwB,CAAC,IAAG,CAAC,MAAM,CAAC,QAAQ;CAChE;;AAlBH,AAoBE,gCApB8B,CAM/B,CAAC,AAcC,OAAO,CAAC;EACR,gBAAgB,EJtCoB,OAAO;EIuC3C,gBAAgB,EAAE,8CAAgD;EAClE,aAAa,EAAE,GAAG;EAClB,UAAU,EAAE,CAAC,CAAC,GAAG,CAAC,GAAG,CAAC,mBAAoB;EAC1C,MAAM,EAAE,IAAI;EACZ,MAAM,EHzBa,IAAI;EG0BvB,KAAK,EAAE,IAAI;CACX;;AAIH,UAAU,CAAV,wBAAU;EACT,IAAI;IACH,SAAS,EAAE,YAAc;;EAE1B,EAAE;IACD,SAAS,EAAE,cAAgB"} */

ESTRELLA Pharma – Affy Pharma Pvt Ltd

TREPODOX

POWDER FOR ORAL SUSPENSION
30ML (HDPE BOTTLE)

Composition

Cefpodoxime 50mg/5ml

Indications & Uses

UTIs, LRTs

TREPODOX – CV

POWDER FOR ORAL SUSPENSION
30ML (GLASS BOTTLE)

Composition

Cefpodoxime 50mg + Potassium Clavulanate 31.25mg/ 5ml

Indications & Uses

Upper & lower respiratory infections, Uncomplicated skin infections, Urinary Tract Infections

ESTY CLAV

POWDER FOR ORAL SUSPENSION
30ML (GLASS +HDPE BOTTLE)

Composition

Amoxycillin 200mg + Potassium clavulanate 28.50 mg/ 5ml

Indications & Uses

Community Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Upper Respiratory Tract Infections, Urinary Tract Infections

ESTRIXIME – CV

POWDER FOR ORAL SUSPENSION
30ML (GLASS BOTTLE)

Composition

Cefixime 50mg + Potassium clavulanate 31.25mg/5ml

Indications & Uses

Urinary Tract Inefctions, AECB, Otitis Media, Typhoid/p>

ESTRIXIME

POWDER FOR ORAL SUSPENSION
30ML (HDPE BOTTLE)

Composition

Cefixime 50mg/5ml

Indications & Uses

Urinary Tract Inefctions, Gastroenteritis

REOMELL

ORAL SUSPENSION
15 ml

Composition

Azithromycin 200mg/5ml

Indications & Uses

Community Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis,

TAMEST – DS

ORAL SUSPENSION
60 ml

Composition

Paracetamol 250mg/5ml

Indications & Uses

Fever, Pain

STREFEN

ORAL SUSPENSION
60 ml

Composition

Paracetamol 125mg + Mefenamic Acid 50mg/5ml

Indications & Uses

Pain, Fever

STREFOX

ORAL SUSPENSION
30 ml

Composition

Ofloxacin 50mg/5ml

Indications & Uses

Acute exacerbations of chronic Bronchitis, Diarrhoea

TAMACET-P

SYRUP
60 ml

Composition

Paracetamol 125mg + PPH 5mg + Cetirizine HCI 2mg/5ml

Indications & Uses

Fever, common cold & Flu

HEPTRELL

ORAL SUSPENSION
200ml

Composition

Cyproheptadine HCI 2mg + Tricholine citrate 0.275mg/5ml

Indications & Uses

Stimulate Apetite, Induces Weight Gain, Cure Allergies

TREP-DSR

CAPSULES ( HARD GELATIN)
10X10 (Alu-Alu)

Composition

Pantoprazole 40mg (EC) + Domperidone 30mg (SR)

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

RALE-DSR

CAPSULES ( HARD GELATIN)
11X10 (Alu-Alu)

Composition

Rabeprazole 20mg (EC) + Domperidone SR

Indications & Uses

GERD, Dyspepsia, Acid Peptic Disorders, Gastritis

STRETOP-40

INJECTION
40ml

Composition

Pantoprazole Sodium 40mg + NaCL

Indications & Uses

Acid-peptic disorders in hospitalized patients, Zollinger – Ellison Syndrome, Treatment of GERD Associated with Erasive Esophagitis, GL Bleed

DIMACID

SUSPENSION
170ml

Composition

Activated Dimethicone 25mg + Magnesium Hydroxide 200mg+ Aluminium Hydroxide Gel 200mg/10ml

Indications & Uses

Heartburn, Acid Indigestion

ELLAZYME

SYRUP
200ml

Composition

Alpha Amylase (1:2000) 50mg, Pepsin(1:3000) 10mg/5ml

Indications & Uses

Dyspepsia, Flatulence, Anorexia, Pancreatic Insufficiency

ARBOLL-Z

CAPSULES (HARD GELATIN)
10X3X10

Composition

Vitamin C 75mg + Vitamin B12 5mcg + Carbonyl Iron 100mg + Folic Acid 1.5mg + Zinc Sulphate 61.8mg

Indications & Uses

Hyphocromic Anemia in Pregnancy, Chronic and / or Acute Blood Loss, Post-gynaesurgery, Iron Deficiency Anemia

EST-D3 60K

CAPSULES (SOFT GELATIN)
10X1X4

Composition

Cholecalciferol 60000 UI

Indications & Uses

Osteoporosis, Osteoarthritis, Musculoskeletal Pain, Type- 2 Diabetes, Menstrual Irregularities, Pre-eclampsia, IUGR

STREBONA

ORAL SUSPENSION
200ml

Composition

Calcium Carbonate 625mg, Vitamin D3 125 IU/5ml

Indications & Uses

Osteomalacia, Osteoporosis, Fractures, Premenstrual Syndrome

STREFE-III

SYRUP (IRON TONIC)
300 ml

Composition

Iron (III) Hydroxide Polymaltose 50mg, Folic Acid 0.5mg/15ml

Indications & Uses

Pregnancy and lactation, Iron Deficiency Anaemia, Anaemia due to Excessive Haemorrhage, Anaemia Associated with Infections and Malignant Disease

STRECIUM

CAPSULES (SOFT GELATIN)
5X2X15

Composition

Calcitriol 0.25mcg + Calcium Carbonate 500mg + Zinc Sulphate 7.5mg

Indications & Uses

Osteoporosis, Hypoparathyroidism, Pregnancy & Lactation, Premenstrual Syndrome

ESTRE-SPAS

TABLETS
20X10

Composition

Mefenamic Acid 250mg + Dicyclomine HCI 10mg

Indications & Uses

Dysmenorrhea, Irritable Bowel Syndrome, Colic and Bladder Spasm, Abdominal Pain

TAMEST-A

TABLETS (BLISTERS)
20X10

Composition

Nimeulide 100mg + Paracetamo; 325mg

Indications & Uses

Arthritis Pain, Soft Tissue Trauma Including Sprains, Musculoskeletal Pain, Pain Following Dental Extraction

PARTRA FORTE

TABLETS

20X10

Composition

Tramadol 37.5mg + Paracetamol 325mg

Indications & Uses

Chronic Back Pain, Osteoarthritis, Postoperative Pain

UMRELY GEL

GEL
30g

Composition

Diclofenac Diethylamine 1.16% w/w + Oleum Linseed Oil 3 % w/w + Menthol 5% w/w +Methyl Salicylate 10% w/w

Indications & Uses

Sprains & Strains, Lower Back Pain, Joint Pain, Knee Pain

MOISTACT

CREAM
20g

Composition

Urea 10% +Lactic Acid 10% + Propylene Glycol 10% + Liquid Paraffin 10%

Indications & Uses

Foot Cracks, Keratolytic

BELODIP

OINTMENT
15g

Composition

Clotrimazole 1% w/w + Beclomethasone Dipropionate 0.025% w/w + Neomycin 0.5% w/w

Indications & Uses

Eczema, Psoriasis, Corticosteroid Responsive Dermatoses

MIN-DAND

LOTION
100 ml

Composition

Ketoconazole 2% w/v

Indications & Uses

Pityriasis, Dandruff

MIN-DAND-Z

LOTION
100 ml

Composition

Ketoconazole Shampoo 2% w/v + ZPTO 1% w/v

Indications & Uses

Pityriasis, Dandruff

MIN-DAND

SOAP
75g

Composition

Ketoconazole 1% w/w

Indications & Uses

Tinea Versicolor, Prophylaxis of Pityriasis Versicolor

FLUTRELLA

TABLETS
20X1X1

Composition

Fluconazole 200mg

Indications & Uses

Vaginal Candidiasis, Brochopulmonary Infections, Candiduria, Tinea Pedis, Corposis, Cruris, Versicolor

ESTRAVIT

SYRUP
200ml

Composition

L-Iysine HCI 25mg + Vitamin B1 2.5mg + Vitamin B2 2.5mg + Vitamin B6 0.75mg + D-panthenol 3mg +Niacinamide 25mg + Mecobalamin 2mcg/10ml

Indications & Uses

Sub-optimal Growth, Poor Weight Gain, Malnutrition, Prolonged Illness

LYCOSTER PLUS

SYRUP
225ml

Composition

Each 10ml Contains: Lycopene 6% 1000mcg + Vitamin A Palmitate 2500 IU + Vitamin E 10 IU + Ascorbic Acid 50mg + Selenium (as Sodium Selenate) 35mcg + Zinc (As Zinc Gluconate) 3mg + Manganese (as Manganese Gluconate) 2mg + Iodine ( As Potassium Iodine) 100mcg + Copper (As Copper Sulphate0 500mcg + Thiamine HCI 2mg + Riboflavine 3mg + Pyridoxine HCI 1.5mg

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

OSERON

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Antioxidant, Multivitamin & Multiminerals

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

GERMELLA

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Vitamin E (Natural) 400 IU + Wheat Germ Oil 100mg + Omega 3 Fatty Acids 30mg

Indications & Uses

Ulcerative colitis, Metabolic Syndrome, Rheumatoid Arthritis, Type-2 Diabetes, Cardiovascular Diseases

LYCOSTER GOLD

CAPSULES (SOFT GELATIN)
10X1X10

Composition

Each SG Contains Lycopene 6% 2000 IU + Vitamin A 2500 IU + Vitamin E Acetate 10 IU + Vitamin C 50 mg + Zinc sulphate Monohydrate 27.45mg + Selenium Dioxide 70mcg

Indications & Uses

Idiopathic Male Infertility, Pre-eclampsia, Prostate Cancer, Cardiovascular Diseases, Diabetes Mellitus

OSERON -G

CAPSULES (SOFT GELATIN)
10X1X11

Composition

Ginseng + Multivitamin + Multimineral

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

OSERON -G

CAPSULES (SOFT GELATIN)
10X1X11

Composition

Ginseng + Multivitamin + Multimineral

Indications & Uses

Tiredness, Stress, Feeling of Weakness, Vitality Deficiency

ESTRIXIME-200 LB

TABLETS (Alu-Alu)
20X10

Composition

Cefixime 200mg + Lactic Acid Bacilus 2.5 billion spores

Indications & Uses

Otitis Media, Pharyngitis & Tonsillitis, Uncomplicated Urinary Tract Infections, Acute Exacerbations of Chronic Bronchitis, Enteric Fever

ESTRIXIME-CV-325

TABLETS (Alu-Alu)
10X1X6

Composition

Cefixime 200mg + Potassium Clavulanate 125mg

Indications & Uses

Respiratory Tract Infections, Urinary Tract Infections, Skin & Skin Structure Infections

ESTY CLAV-625 LB

TABLETS (Alu-Alu)
10X1X6

Composition

Amoxycillin 500mg + Potassium Clavulanate 125mg

Indications & Uses

Respiratory Tract Infections, Community Acquired Pneumonia, Gynaecological Infections, Acute Exacerbations of Chronic Bronchitis, Skin and Soft Tissue Infections

FLOXEST

TABLETS (Blister)
20X10

Composition

Ofloxacin 200mg + Ornidazole 500mg

Indications & Uses

Surgical ions, Diarrheas of Mixed Etiology, Gynaecological Infections, Orofacial and Dental Infections

VOFLOX-500

TABLETS
10X10

Composition

Levofloxacin 500mg

Indications & Uses

Acute Bacterial Sinusitis, Acute Bacterial Exacerbations of Chronic Bronchitis, Skin & Skin Structure Infections, Chronic Bacterial Prostatitis, Urinary Tract Infections

FLOXEST – O

TABLETS (Alu-Alu)
20X10

Composition

Cefixime 200mg + Ofloxacin 200mg

Indications & Uses

Community Acquired Pneumonia, Multiple Drug Resistant-TB, Typhoid

FLOXEST

TABLETS (Alu-Alu)
20X10

Composition

Ofloxacin 200mg

Indications & Uses

Community Acquired Pneumonia, Multiple Drug Resistant-TB, Typhoid

ESTY CLAV- 1.2

INJECTIONS
1.2g

Composition

Amoxycillin 1000mg + Potassium Clavulanate 200mg + WFI

Indications & Uses

Community Acquired Pneumonia, Gynaecological Infections, Upper Respiratory Tract Infections, Skin and Soft Tissue Infections, Urinary Tract Infections, Acute Exacerbations of Chronic Bronchitis

TRELLON-SB 1.5

INJECTIONS
1.5g

Composition

Ceftriaxone 1000mg + Sulbactam 500mg + WFI

Indications & Uses

Gynaecological Infections, Lower Respiratory Tract Infections, Intra-abdominal Infections with Aerobic Organisms, Surgical Prophylaxis

TRELLON-TZ 1.125

INJECTIONS
1.125gm

Composition

Ceftriaxone 1000mg + Tazobactam 500 mg + WFI

Indications & Uses

Bone & Joint Infections, Intra-abdominal Infections, Bacterial Meningitis, Pre-operative Surgical Prophylaxis

RELLAM

INJECTIONS
1gm

Composition

Meropenem 1gm + WFI

Indications & Uses

Complicated Intra-abdominal Infection (cIAI), Complicated Skin & Skin Structure Infections (cSSSI), Bacterial Meningitis, Noscocomial Pneumonia

TRELIN-Z 4.5

INJECTIONS
4.5gm

Composition

Piperacillin 4000mg + Tazobactam 500mg + WFI

Indications & Uses

Intra-abdominal Infections, Complicated Urinary Tract Infections, Febrile Neutropenia, Lower Respiratory Tract Infections

TRELIN-Z 4.5

INJECTIONS
4.5gm

Composition

Piperacillin 4000mg + Tazobactam 500mg + WFI

Indications & Uses

Intra-abdominal Infections, Complicated Urinary Tract Infections, Febrile Neutropenia, Lower Respiratory Tract Infections

BUTRELLA

SYRUP

100ml

Composition

Ambroxol HCI 15mg + Guaiphensin 50mg + Terbutaline Sulphate 1.5mg + Mentholated Base/5ml

Indications & Uses

Bronchitis, Productive Cough, Emphysema, Bronchial Asthma

BUTRELLA-BR

SYRUP

100ml

Composition

Terbutaline Sulphate 1.25mg + Bromhexine HCI 4mg + Guaiphenesin 50mg + Methalated Base/5ml

Indications & Uses

Acute Cough, Abnormal Mucus Secretion, Productive Cough

DEXTRIN

SYRUP
100ml

Composition

Dextromethorphan Hydrobromide 10mg + Phenylpherine 5 mg + Cetrizine 5mg + Mentholated Base/5ml

Indications & Uses

Commom Cold and Flu, Nasal Congestion, Sore Throat

VOTRELL-M

TABLETS (Alu-Alu)
20X10

Composition

Levocetirizine 5mg + Montelukast 10mg

Indications & Uses

Allergic Rhinitis, Nasal Congestion, Asthma

VOTRELL

TABLETS (Alu-Alu)
20X11

Composition

Levocetirizine 5mg

Indications & Uses

Chronic Idiopathic Urticaria (CIU), Seasonal Allergic Rhinitis (SAR), Perennial Allergic Rhinitis (PAR)

Arrange A Callback
[]
1 Step 1
Full Name
Telephone
Departmentyour full name
Postal Address
Message
0 /
Previous
Next
Shopping Basket